CareersPipelineCollaboration RareInnovation SVGOMG The best SVG optimizer and minifier Open SVG Paste markup Demo Contribute SVGOMG provides you several options to clean and compress your SVG files. Clean up, remove, merge, minify. Upload or copy the source of your SVG to get started! 947 bytes → 267 bytes 28.19% Finance peopleAdvance treatment Skip to main contentSkip to navigationSkip to search
HNSA   ( ,  %) SEK
Quotes are delayed 15 minutes

Hansa Medical to present at Jefferies 2017 Global Healthcare Conference

7 Jun 2017, 08:00
Regulatory information
Hansa Medical will present at the Jefferies 2017 Global Healthcare Conference on June 9 in New York City. Göran Arvidson, Chief Executive Officer, will present at the conference at 1:00 p.m. EDT. (7:00 p.m. CEST).

A live audio webcast of the presentation will be accessible through the Hansa Medical website www.hansamedical.com and through the following link: http://wsw.com/webcast/jeff105/hmed 

The information was submitted for publication, through the agency of the contact person set out below, at 8 am CEST on June 7, 2017. 

Files

For further information, please contact:
Hansa Medical AB (Publ)
Emanuel Björne, Vice President Business Development and Investor Relations
Mobil: +46707175477
E-mail: emanuel.bjorne@hansamedical.com

Cord Communications, Stockholm
Mikael Widell
Mobile: +46 70 311 9960

Lars Wahlström
Mobile: +46 73 434 0771

FTI Consulting, London
Julia Phillips / Stephanie Cuthbert / Hanna Skeppner: +44 203 727 1000

About Hansa Medical AB
Hansa Medical is a biopharmaceutical company developing novel immunomodulatory enzymes for transplantation and acute autoimmune diseases. The lead project IdeS is a proprietary antibodydegrading enzyme currently in late- stage clinical development for kidney transplant patients, with significant potential for further development in other solid organ transplants and a wide range of acute autoimmune indications. The company also has a strong pipeline of preclinical assets that may provide a second wave of potential drugs. Under the project name NiceR, novel immunoglobulin cleaving enzymes are developed for repeat dosing translating the Hansa Medical technology into relapsing autoimmune diseases and oncology. Hansa Medical is based in Lund, Sweden, its shares (ticker: HMED) are listed on Nasdaq Stockholm.